TLT Insider Trading

Insider Ownership Percentage: 8.14%
Insider Buying (Last 12 Months): C$176.49
Insider Selling (Last 12 Months): C$0.00

Theralase Technologies Insider Trading History Chart

This chart shows the insider buying and selling history at Theralase Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theralase Technologies Share Price & Price History

Current Price: C$0.16
Price Change: Price Increase of +0.005 (3.23%)
As of 05/22/2024 04:14 PM ET

This chart shows the closing price history over time for TLT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Theralase Technologies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2024Matthew Thomas PerratonDirectorBuy900C$0.20C$176.49900
4/18/2022Roger John Dumoulin-WhiteDirectorBuy32,000C$0.32C$10,240.007,576,387
4/6/2022Roger John Dumoulin-WhiteDirectorBuy20,000C$0.32C$6,300.007,544,387
12/16/2021Roger John Dumoulin-WhiteDirectorBuy33,300C$0.30C$9,990.007,524,387
10/1/2021Roger John Dumoulin-WhiteDirectorBuy50,000C$0.20C$10,000.007,491,087
9/22/2021Kristina Maria HacheySenior OfficerBuy50,000C$0.20C$10,000.001,756,267
9/10/2021Roger John Dumoulin-WhiteDirectorBuy45,000C$0.22C$9,900.007,441,087
See Full Table

SEC Filings (Institutional Ownership Changes) for Theralase Technologies (CVE:TLT)

Theralase Technologies logo
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.
Read More on Theralase Technologies

Today's Range

Now: C$0.16
Low: C$0.16
High: C$0.17

50 Day Range

MA: C$0.17
Low: C$0.16
High: C$0.21

52 Week Range

Now: C$0.16
Low: C$0.15
High: C$0.31

Volume

73,153 shs

Average Volume

122,270 shs

Market Capitalization

C$38.29 million

P/E Ratio

N/A

Dividend Yield

2.03%

Beta

1.59

Who are the company insiders with the largest holdings of Theralase Technologies?

Theralase Technologies' top insider shareholders include:
  1. Matthew Thomas Perraton (Director)
Learn More about top insider investors at Theralase Technologies.